Gilead hepatitis C drug sales slump, shares fall 5%
Gilead Sciences reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent. The company left […]